Business Context and Reporting Period
Company: Integer Holdings Corp (ITGR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 26, 2025
Business Overview: Integer is a medical device contract development and manufacturing organization (CDMO) serving cardiac rhythm management, neuromodulation, and cardio/vascular markets. The company operates as a single segment.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Sales | $467,691 | $431,417 | $1,381,577 | $1,267,099 |
| Gross Profit | $126,160 | $116,568 | $375,630 | $342,218 |
| Gross Margin | 27.0% | 27.0% | 27.2% | 27.0% |
| Operating Income | $56,439 | $58,011 | $165,329 | $151,206 |
| Net Income | $39,678 | $35,439 | $54,200 | $87,193 |
| Diluted EPS | $1.11 | $0.99 | $1.52 | $2.46 |
| Cash from Operations (9M) | $140,733 (2025) vs $141,974 (2024) | |||
| Debt (Long-term) | $1,193,826 (Sep 26, 2025) vs $980,153 (Dec 31, 2024) | |||
| Cash & Equivalents | $58,944 (Sep 26, 2025) vs $46,543 (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 8.4% in Q3 and 9.0% in the first nine months of 2025 compared to 2024. Growth was driven by the Cardio & Vascular segment (+15% Q3, +19% 9M) and contributions from recent acquisitions (Precision Coating and VSi Parylene).
- Profitability: While Q3 operating income decreased slightly ($1.6M) due to higher operating expenses, 9M operating income increased 9.3%. Net income for the 9M period decreased 38.4% primarily due to a one-time non-cash charge.
- Unusual Items: The 9M 2025 results include a $46.7 million debt conversion inducement expense recorded in Q1 2025 related to the partial exchange of 2028 Convertible Notes. This significantly impacted the effective tax rate (31.0% for 9M 2025 vs 18.7% for 9M 2024) and net income.
- Restructuring: Restructuring and other charges increased to $16.4M for 9M 2025 from $10.5M in 2024, driven by $6.2M in termination benefits to align labor with manufacturing volumes and acquisition integration costs.
- Debt Structure: In March 2025, the company issued $1.0 billion in 2030 Convertible Notes. Proceeds were used to exchange $383.7M of 2028 Notes, pay down the Term Loan A facility, and fund capped call transactions. Total long-term debt increased to $1.19 billion.
Guidance, Outlook, and Risks
- Acquisitions: The company completed acquisitions of Precision Coating LLC ($153.5M consideration) and VSi Parylene ($24.0M consideration) in early 2025 to expand coating capabilities. Contingent consideration (earn-outs) totaling up to $9.0M is possible based on future revenue milestones.
- Market Exit: The company is executing a planned exit from the Portable Medical market, expected to conclude in Q4 2025. This contributed to a 31% decline in "Other Markets" sales for the 9M period.
- Liquidity: The company maintains a strong liquidity position with $58.9M in cash and $794.7M available under its Revolving Credit Facility. Management believes cash flows and borrowing capacity are sufficient for the next 12 months.
- Risks: Key risks include dependence on a limited number of customers (top 3 customers represent ~49% of revenue), supply chain disruptions, geopolitical factors, and the potential dilution from convertible notes if conversion conditions are met.
- Tax Reform: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 but does not anticipate a material immediate impact.
Investor Verification Checklist
- Debt Conversion Impact: Verify the non-recurring nature of the $46.7M inducement expense and its specific impact on the 9M 2025 effective tax rate and net income.
- Acquisition Integration: Monitor the revenue contribution and integration costs associated with the Precision and VSi acquisitions to ensure they meet projected milestones.
- Convertible Note Terms: Review the conversion triggers for the 2028 and 2030 Convertible Notes, as stock price performance could lead to dilution or cash outflows.
- Portable Medical Exit: Track the finalization of the Portable Medical market exit in Q4 2025 and its impact on the "Other Markets" revenue line.
- Working Capital Trends: Observe the increase in accounts receivable and inventory, which grew alongside sales volume, to ensure collection and inventory turnover remain healthy.